Sonrotoclax
Based on 1 Customer Validation
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.61%
- CAS 番号: 2383086-06-2
- 分子式: C49H59N7O7S
- 分子量:890.10
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MOLT-4 | IC50 |
2493 nM
Compound: 12e; BGB-11417
|
Inhibition of cell growth in human MOLT-4 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay
Inhibition of cell growth in human MOLT-4 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 38695063] |
| RS4-11 | IC50 |
0.56 nM
Compound: 12e; BGB-11417
|
Inhibition of cell growth in human RS4-11 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay
Inhibition of cell growth in human RS4-11 cells incubated for 2 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 38695063] |
| RS4-11 | IC50 |
7 nM
Compound: 12e; BGB-11417
|
Inhibition of cell growth in human RS4-11 cells harboring Bcl-2 G101V mutant incubated for 2 days by CellTiter-Glo luminescent cell viability assay
Inhibition of cell growth in human RS4-11 cells harboring Bcl-2 G101V mutant incubated for 2 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 38695063] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NCG mice with acute lymphoblastic leukemia (ALL) xenografts[1]
-
Dosage:5, 15, 50 mg/kg
-
Administration:oral administration; daily, for 42 days
-
Result:Inhibited tumor growth in a dose-dependent manner.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2383086-06-2
-
性状 Solid
-
分子量 890.10
-
分子式 C49H59N7O7S
-
Color Light yellow to yellow
-
SMILES
CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C
-
別名
BGB 11417
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 100 mg/mL (112.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (2.81 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (2.81 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1235 mL | 5.6173 mL | 11.2347 mL | 28.0867 mL |
| 5 mM | 0.2247 mL | 1.1235 mL | 2.2469 mL | 5.6173 mL | |
| 10 mM | 0.1123 mL | 0.5617 mL | 1.1235 mL | 2.8087 mL | |
| 15 mM | 0.0749 mL | 0.3745 mL | 0.7490 mL | 1.8724 mL | |
| 20 mM | 0.0562 mL | 0.2809 mL | 0.5617 mL | 1.4043 mL | |
| 25 mM | 0.0449 mL | 0.2247 mL | 0.4494 mL | 1.1235 mL | |
| 30 mM | 0.0374 mL | 0.1872 mL | 0.3745 mL | 0.9362 mL | |
| 40 mM | 0.0281 mL | 0.1404 mL | 0.2809 mL | 0.7022 mL | |
| 50 mM | 0.0225 mL | 0.1123 mL | 0.2247 mL | 0.5617 mL | |
| 60 mM | 0.0187 mL | 0.0936 mL | 0.1872 mL | 0.4681 mL | |
| 80 mM | 0.0140 mL | 0.0702 mL | 0.1404 mL | 0.3511 mL | |
| 100 mM | 0.0112 mL | 0.0562 mL | 0.1123 mL | 0.2809 mL |
Sonrotoclax 関連分類
HY-148026 関連分類
Powered by Bioz